To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
765 Newest Publications in british journal of clinical pharmacology
rss
Junior doctors’ perceptions of their self‐efficacy in prescribing, their prescribing errors and the possible causes of errors
30-04-2013 | Cristín Ryan, Sarah Ross, Peter Davey, Eilidh M Duncan, Shona Fielding, Jill J Francis, Marie Johnston, Jean Ker, Am ..., British Journal of Clinical Pharmacology, 2013
Summary Aims Explore and compare junior doctors’ perceptions of their self‐efficacy in prescribing, their prescribing errors and the possible causes of those errors. Methods A cross‐sectional questionnaire study was distributed to foundation doctors throughout Scotland, based on ...
Not‐in‐trial simulation I: bridging cardiovascular risk from clinical trials to real life conditions
25-04-2013 | ASY Chain, JP Dieleman, C Noord, A Hofman, BHC Stricker, M Danhof, MCJM Sturkenboom, O Della Pasqua, British Journal of Clinical Pharmacology, 2013
Summary Aim he assessment of QTc interval prolongation relies on the evidence of drug effects in healthy subjects. This study demonstrates the relevance of pharmacokinetic‐pharmacodynamic (PKPD) relationships to characterise drug‐induced QTc‐interval prolongation and explore the ...
Overview of Methods for Comparing the Efficacies of Drugs in the Absence of Head‐to ‐Head Clinical Trial Data
25-04-2013 | Hansoo Kim, Lyle Gurrin, Zanfina Ademi, Danny Liew, British Journal of Clinical Pharmacology, 2013
Abstract/Summary In most therapeutic areas, multiple drug options are increasingly becoming available, but there is often a lack of evidence from head‐to‐head clinical trials that allow for direct comparison of the efficacy and/or safety one drug versus another. This review provides an ...
Incidence and Risk of hypertension with a novel multitargeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
25-04-2013 | Wei‐Xiang Qi, Ai‐Na He, Zan Shen, Yang Yao, British Journal of Clinical Pharmacology, 2013
Abstracts Purposes To investigate the overall incidence and risk of hypertension in cancer patients who receive axitinib and compare the differences in incidences between axitinib and other four approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor ...
Junior Doctor‐Led ‘Near‐Peer’ Prescribing Education for Medical Students
25-04-2013 | Kyle R Gibson, Zeshan U Qureshi, Michael T Ross, Simon R Maxwell, British Journal of Clinical Pharmacology, 2013
Structured Summary Aims Prescribing errors are common and inadequate preparation of prescribers appears to contribute. A junior doctor‐led prescribing tutorial programme has been developed for Edinburgh final year medical students to increase exposure to common prescribing tasks. The ...
Towards a universal influenza vaccine: Volunteer virus challenge studies in quarantine to speed the development and subsequent licensing
25-04-2013 | J.S. Oxford, British Journal of Clinical Pharmacology, 2013
Abstract There are now more than ten experimental vaccine formulations which induce T and B cell immunity towards the internally situated virus proteins matrix (M1 and M2e) and nucleoprotein (NP), and towards stem and stalk regions of the HA which have a shared antigenic structure amongst ...
Population pharmacokinetic‐pharmacodynamic analysis for eribulin mesilate associated neutropenia
19-04-2013 | Hasselt J. G. Coen, Gupta Anubha, Hussein Ziad, Beijnen Jos H., Schellens Jan H. M., Huitema Alwin D. R., British Journal of Clinical Pharmacology, 2013
Summary Aims Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late stage metastatic breast cancer. Neutropenia is one of the major dose‐limiting adverse effects of eribulin. The objective of this analysis was to develop a population ...
The combined use of disease activity and infliximab serum trough levels for early prediction of (non‐)response to infliximab in rheumatoid arthritis
19-04-2013 | B J F Bemt, A A Broeder, G J Wolbink, A Maas, Y A Hekster, Piet L C M Riel, H B Benraad, F HJ Hoogen, British Journal of Clinical Pharmacology, 2013
Abstract Aim Early prediction of (non‐)response to infliximab therapy can improve therapeutic benefit by avoiding unnecessary periods of high disease activity during ineffective therapy. This prospective cohort study therefore aims to study the predictive value of (1) disease activity ...
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects
19-04-2013 | L E Klumpers, M Fridberg, M L Kam, P B Little, N O Jensen, H D Kleinloog, C E Elling, J M A Gerven, British Journal of Clinical Pharmacology, 2013
Summary Aim Cannabinoid receptor type 1 (CB1) antagonists show central side effects, whereas beneficial effects are most likely peripherally mediated. In this study, peripherally selective CB1 antagonist TM38837 was studied in humans. Methods This was a double‐blind, randomized, ...
Bisphosphonate Use and Risk of Colorectal Cancer: A Systematic Review and Meta‐analysis
18-04-2013 | Stefanos Bonovas, Georgios Nikolopoulos, Pantelis Bagos, British Journal of Clinical Pharmacology, 2013
Summary Aim A growing body of evidence suggests that bisphosphonates may have chemopreventive potential against colorectal cancer. Our aim was to examine this association through a meta‐analysis of observational studies. Methods A comprehensive search for relevant articles ...
Netmeeting
